Belrestotug is a monoclonal antibody commercialized by iTeos Therapeutics, with a leading Phase II program in Solid Tumor. According to Globaldata, it is involved in 9 clinical trials, of which 2 were completed, 6 are ongoing, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Belrestotug’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Belrestotug is expected to reach an annual total of $366 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Belrestotug Overview
EOS-448 is under development for the treatment of solid tumors, non-small cell lung cancer, squamous non-small cell lung cancer, PD-1 resistant melanoma and head and neck cancer squamous cell carcinoma. It is administered through intravenous route. The drug candidate is a checkpoint blocking antibody acts by targeting TIGIT.
It was also under development for the treatment of relapsed or refractory multiple myeloma.
iTeos Therapeutics Overview
iTeos Therapeutics is a clinical-stage biopharmaceutical company that primarily focuses on the discovery and development of immuno-oncology therapeutics. The company’s pipeline products include Belrestotug (EOS-448), Inupadenant, and EOS-984. iTeos Therapeutics’ products are primarily used in the healthcare industry, specifically in the treatment of patients with advanced solid tumors. Its service includes to carries out clinical trials for inupadenant, an A2A receptor antagonist, as a treatment for solid tumors in monotherapy. The company operates in Belgium and the US. iTeos Therapeutics is headquartered in Cambridge, Massachusetts, the US.
The company reported revenues of (US Dollars) US$12.6 million for the fiscal year ended December 2023 (FY2023), a decrease of 95.3% over FY2022. The operating loss of the company was US$151.1 million in FY2023, compared to an operating profit of US$126.3 million in FY2022. The net loss of the company was US$112.6 million in FY2023, compared to a net profit of US$96.7 million in FY2022.
For a complete picture of Belrestotug’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
